DMK Pharmaceuticals Announces Inducement Option Grant Under Nasdaq Listing Rule 5635(c)(4)
2023年10月30日 - 8:30PM
DMK Pharmaceuticals Corporation (NASDAQ: DMK), a commercial-stage
biopharmaceutical company, today announced that the compensation
committee of the board of directors approved the grant of a stock
option on October 23, 2023, to purchase an aggregate of 70,000
shares of common stock to John W. Dorbin, Jr., a newly hired
employee who was appointed as General Counsel and Corporate
Secretary of the company. The stock option was granted as a
material inducement to his acceptance of employment in accordance
with Nasdaq Listing Rule 5635(c)(4). The stock option has a
ten-year term and has an exercise price of $0.58 per share,
the closing price of the company’s common stock on the grant date.
The option vests over a four year period, with the option vesting
and becoming exercisable with respect to one-eighth of the shares
subject to the option on the six month anniversary of the date of
first employment and thereafter monthly with respect to 1/48 of the
total number of shares subject to the option, provided that the
optionee continues to provide service to the company through the
applicable vesting dates. The stock option was granted outside of
the company’s 2020 Equity Incentive Plan.
About DMK Pharmaceuticals
DMK Pharmaceuticals is a commercial stage neuro-biotech company
primarily focused on developing and commercializing products for
the treatment of opioid overdose and substance use disorders. DMK’s
commercial products approved by the FDA include ZIMHI® (naloxone)
Injection for the treatment of opioid overdose, and SYMJEPI®
(epinephrine) Injection for use in the emergency treatment of acute
allergic reactions, including anaphylaxis. The company is focused
on developing novel therapies for opioid use disorder (OUD) and
other important neuro-based conditions where patients are currently
underserved. The company’s lead clinical stage product candidate,
DPI-125, is being studied as a potential novel treatment for OUD.
DMK also plans to develop the compound for the treatment of
moderate to severe pain. The company’s other development stage
product candidates include DPI-221 for bladder control problems and
DPI-289 for severe end stage Parkinson’s disease. For additional
information about DMK Pharmaceuticals, please visit our website and
follow us on Twitter and LinkedIn.
Investor and Media Contact:Maria YonkoskiICR
Westwicke203-682-7167
DMK Pharmaceuticals (NASDAQ:DMK)
過去 株価チャート
から 5 2024 まで 6 2024
DMK Pharmaceuticals (NASDAQ:DMK)
過去 株価チャート
から 6 2023 まで 6 2024